Wyeth, GSK Vaccines May Get Sales Boost Under Pilot For Developing Countries
Executive Summary
Pediatric pneumococcal vaccines in development by Wyeth and GlaxoSmithKline could be the first products to benefit from a pilot program designed to create an incentive to develop vaccines that treat the diseases of the developing world
You may also be interested in...
BIO maps incentives for neglected diseases
The Biotechnology Industry Organization highlights incentives for innovation for diseases in developing countries, including Advanced Market Commitments, R&D tax incentives, priority review vouchers, transferable exclusivity, Track II patents and even prizes in the paper released June 18 at the BIO International Convention in San Diego, Calif. Some of the incentives are already being adopted. For example, the FDA Amendments Act includes a mechanism to encourage development of tropical diseases - including AIDS - by offering sponsors a transferable priority review voucher. Additionally, an investigational version of Wyeth's currently marketed Prevnar is an anticipated candidate for a pediatric pneumococcal AMC, as is an investigational vaccine, Streptorix, being developed by GlaxoSmithKline (1"The Pink Sheet," Nov. 26, 2007, p. 24)
BIO maps incentives for neglected diseases
The Biotechnology Industry Organization highlights incentives for innovation for diseases in developing countries, including Advanced Market Commitments, R&D tax incentives, priority review vouchers, transferable exclusivity, Track II patents and even prizes in the paper released June 18 at the BIO International Convention in San Diego, Calif. Some of the incentives are already being adopted. For example, the FDA Amendments Act includes a mechanism to encourage development of tropical diseases - including AIDS - by offering sponsors a transferable priority review voucher. Additionally, an investigational version of Wyeth's currently marketed Prevnar is an anticipated candidate for a pediatric pneumococcal AMC, as is an investigational vaccine, Streptorix, being developed by GlaxoSmithKline (1"The Pink Sheet," Nov. 26, 2007, p. 24)
NIH Public/Private Partner Grants Highlighted At BIO/Gates Forum
The National Institute of Health's initiative to provide grants to public/private partnerships for early-stage research marks one of several collaborative efforts to advance tropical disease and HIV compounds, NIAID Director Anthony Fauci said March 12